JPIAMR joins forces across nations to fight AMR through effective collaborative actions in areas of unmet needs
About JPIAMR
The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) was formed 2011 by 15 European Countries with the support of the European Commission and now comprise 26 countries globally. It is funding 65 M Euros of basic and exploratory research on new antibiotics, stewardship of existing antibiotics, and studies and control of the spread of antibiotic resistance between humans, animals, and the environment in a One Health perspective. It also supports research through several activities such as the establishment of a Virtual Research Institute. JPIAMR coordinate national research programmes on AMR through its Strategic Research Agenda and with input from the IMI and a network of non-governmental stakeholders.
The Challenge – Lives Are at Stake
Antibiotics have saved millions of lives throughout the many decades it has been in use as a common drug. However, antibiotic resistance is now a global health security challenge. When bacteria become resistant to commonly used drugs, society needs to respond with concerted actions. Only together can we divert from a trajectory leading to up to 10 million human lives being extinguished yearly because of antibiotic resistant bacteria, this by 2050 if projections becomes reality. Collaboration is the cornerstone of JPIAMR and collaboration is key – resistant bacteria knows of no nations boarders. Currently, there are few new antibiotics in development.
The JPIAMR – The key to turn the tide of AMR
The Joint Programming Initiative on Antimicrobial Resistance, JPIAMR, is a unique international collaborative platform that coordinates national funding and supports collaborative action for filling knowledge gaps on antimicrobial resistance with a One Health perspective. By mobilising existing and new resources, the JPIAMR creates a greater critical mass and attracts new researchers into the AMR field. Our shared Strategic Research Agenda, outlines the key areas to address and provides guidance for countries to align their AMR research agendas nationally and internationally. This to meet major challenges that no individual country is capable to handle on its own. Today 26 countries have joined JPIAMR as members. The collaborative platform is now internationally recognized. JPIAMR interacts with stakeholders such as WHO, ASEAN, G7 and the USA. G20 and G7 now include activities by JPIAMR in declarations and resolutions. JPIAMR coordinates research priorities and calls with the EC, IMI and pharma industry together with close cooperation with EC DG Research, DG Santé and many efforts aligning with European health authorities. The current platform extends well beyond Europe including members such as Japan, Argentina, South-Africa and other nations. New members are added continuously to this global and unique platform.
The Future – Global Collaboration Creates Transformative Changes
The mission for JPIAMR for the years 2020-2025 is stated as: “To join forces across nations by leading the alignment, coordination, and support to Antimicrobial Resistance One Health collaborative research and global policy activities”.
The overarching major goals are:
- To align national and international research programmes.
- To support and coordinate transformative research.
- To support and coordinate the JPIAMR Virtual Research Institute.
- To promote innovation and translation of research results.
- To bridge the gap between research and policy.
JPIAMR support new evidence and innovations that reduce the burden of antimicrobial resistance through coordinated global collaborative research in Europe and around the world. Also aiming to undertake further research to better understand how resistance develops and spreads in the environment. And to develop diagnostic tools and better surveillance methods as well as validating smarter strategies for using antibiotics in healthcare and agriculture.
JPIAMR will contribute to faster global progress of research and innovation on antimicrobial resistance. To ultimately find new cures and methods to harness drug resistant bacteria. The Virtual Research Institute is a dynamic network of research facilities, changing the way resources are shared and used.
The scientific and societal challenge of AMR is likely to be greater in the next 10 years.
JPIAMR is the key to turn the tide of AMR in Europe and beyond.
Please select the individual countries to reach the member country web pages. European Commission (DG Research) is a non voting member.
